2023 Feb: According to data published in JAMA Oncology, the global economic cost of cancer is projected to reach $25,2 trillion in international dollars (INT) between 2020 and 2050.
Amerika Utara diproyeksikan memiliki biaya tertinggi, dan Cina diproyeksikan memiliki biaya per kapita tertinggi. Kanker trakea, bronkus, dan paru-paru diperkirakan akan menimbulkan biaya tertinggi.
Researchers used a macroeconomic model to make these forecasts. Between 2020 and 2050, they projected the cost of 29 cancers in 204 countries and territories.
The United States ($5,300 billion), China ($6,100 billion), and India ($1,400 billion) will bear the largest economic costs.
Bulgaria (1.42%), Monaco (1.33%), and Montenegro (1.0%) are the countries with the highest projected economic costs as a percentage of gross domestic product. The projected economic cost per capita is greatest in Monaco ($85,230), Ireland ($54,009), and Bermuda ($20,732)
North America is projected to have the highest economic burden from cancer as a proportion of gross domestic product, equivalent to a 0.83 percent annual tax. Europe and Central Asia (0.63%), East Asia and the Pacific (0.59%), and Sub-Saharan Africa (0.24%) follow.
Menurut jenis kanker, biaya ekonomi tertinggi diproyeksikan untuk:
- Kanker trakea, bronkus, dan paru-paru (INT $3.9 triliun)
- Kanker usus besar dan rektum (INT $2.8 triliun)
- Kanker payudara (INT $2.0 triliun)
- Kanker hati (INT $1.7 triliun)
- Leukemia (INT $1.6 triliun)
Para peneliti mencatat bahwa kanker ini menyumbang setengah dari biaya ekonomi global akibat kanker.
The researchers wrote, “The macroeconomic cost of cancer was found to be substantial and heterogeneously distributed across cancer types, countries, and world regions.” The findings indicate that global efforts to reduce the prevalence of cancer are warranted.
Editorial terkait menyoroti keterbatasan penelitian, termasuk tidak adanya data untuk 60 negara, atau 7.3% dari total populasi.
Pengungkapan: Penulis penelitian melaporkan tidak memiliki konflik kepentingan. Penulis editorial menyatakan afiliasi dengan perusahaan bioteknologi, farmasi, dan/atau perangkat. Silakan lihat referensi asli untuk daftar lengkap pengungkapan.
